Multiple Sklerose und COVID-19

Age, higher EDSS (Expanded Disability Status Scale), obesity and comorbidities are known risk factors for severe course of COVID-19 in patients with multiple sclerosis. However, multiple sclerosis per se is not an isolated factor for higher risk of infection with SARS-CoV‑2 or severe course. So far disease-modifying therapy prevalence has not shown a difference in clinical outcome compared to patients without multiple sclerosis, but further confirmation is warranted. Treatment for multiple sclerosis should be continued despite the COVID-19 pandemic. In patients with appropriate indications, initiation of treatment should not be delayed. More analyses of future registry data to confirm the previous observations is desirable and necessary.